How Much Rumored Suitors Like Sanofi Would Have To Pay For Sarepta
Sarepta Therapeutics stock ended last week up over 11% due to the better-than-expected first-quarter sales of its Duchenne muscular dystrophy (DMD) drug Exondys 51, combined with the rumor that the French drugmaker Sanofi may be considering a tender offer in the not-so-distant future.
Although this buyout rumor is based solely on the news that Sarepta's CEO Ed Kaye is stepping down and Sanofi's executive Jean-Paul Kress also decided to leave Sarepta's board of directors due to "a possible conflict of interest associated with his future endeavors," it wouldn't be entirely surprising if Sarepta were making the rounds as a takeover target at this juncture.
Although this buyout rumor is based solely on the news that Sarepta's CEO Ed Kaye is stepping down and Sanofi's executive Jean-Paul Kress also decided to leave Sarepta's board of directors due to "a possible conflict of interest associated with his future endeavors," it wouldn't be entirely surprising if Sarepta were making the rounds as a takeover target at this juncture.